Please login to the form below

Not currently logged in

China’s Innovent to start US trials of anti-CD47 cancer drug

Sintilimab will be initially positioned for the Chinese market


Chinese biotech Innovent Biologics has been given approval by the FDA to start trials of an antibody that targets CD47, an emerging target in immuno-oncology.

Innovent can now start trials of IBI-188 in patients with advanced malignancies and lymphomas, says the biotech, and is the second of its pipeline drugs to be cleared for US trials after PD-1 inhibitor sintilimab (IBI-308) – partnered with Eli Lilly – got a green light earlier this year.

CD47 is a cell membrane receptor belonging to the immunoglobulin (Ig) superfamily, which is found on the surface of many tumour types and seems to protect against their destruction by the immune system by sending out a ‘don’t eat me’ signal to macrophage cells.

Studies have also suggested that blocking CD47 can send some tumour cells into programmed cell death (apoptosis), and the receptor seems to play a key role in the tumour microenvironment, affecting cell growth and migration and blood vessel formation. Some cancer cells express CD47 at very high levels and this seems to correlate with poor survival.

Sintilimab is being positioned initially for the Chinese market, given the wealth of competition in the PD-1/PD-L1 inhibitor category in the US and Europe. But with IBI-188, Innovent has a candidate that is in the running to be one of the first to market in a brand new I-O  category worldwide – and a clear leader in China.

“CD47 … has become a highly researched therapeutic target across the world,” said the company in a statement, noting that there are a few CD47 programmes in phase 1 and 2 testing outside China.

Innovent is facing some well-positioned competition in the CD47 space. A US biotech – Stanford University spinout Forty Seven – is advancing a CD47-targeting antibody called Hu5F9-G4 in mid-stage trials, and has already attracted partnerships with Merck KGaA and Roche who are testing it alongside their checkpoint inhibitors.

Other companies working on CD47 antibodies include Canada's Trillium Therapeutics – whose TTI-621 candidate is in early-stage testing – while US biotechs Arch Oncology and Aurigene and Synthon of the Netherlands have programmes in early development. And earlier this year Boehringer Ingelheim licensed a drug from French biotech OSE Immunotherapeutics that targets SIRP-alpha – which binds to CD47 – in a €1.1bn deal.

Meanwhile, Swiss biotech Novimmune is working on a bispecific antibody that targets CD47 and CD19. The rationale for that dual approach is that CD47 is widely distributed in healthy tissues, and targeting CD19 can help avoid potential ‘off-target’ effects by zeroing in on cancer cells.  The candidate – acquired along with TH Therapeutics in June – is due to start clinical trials next year.

Innovent reckons IB-188 has stronger receptor blocking ability than other investigational drugs against CD47, and says it intends to start several clinical trials across multiple cancers, including non-Hodgkin's lymphoma and ovarian cancer.

Meanwhile, Innovent is now waiting for a regulatory verdict from the Chinese medicines regulator for sintilimab, which was the drug domestically-developed PD-1 inhibitor to be filed for approval in China last December and came just a few weeks after Bristol-Myers Squibb submitted Opdivo (nivolumab).

Article by
Phil Taylor

1st October 2018

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

The other side of … rheumatoid arthritis
For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
How to lessen site burden with a targeted patient recruitment strategy
Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...